ÂÜÀòÂÒÂ×

Mark Treherne is an accomplished professional with extensive experience in the life sciences sector, currently serving as Chairperson for several companies, including Talisman Therapeutics Limited, Ubiquigent Ltd, Monument Therapeutics, and NuVision Biotherapies Ltd. With a background in pharmacology, including a Ph.D. and M.Phil. from the University of Cambridge, Mark Treherne has held key leadership roles, such as Chief Executive at Cellesce Ltd and Avilex Pharma ApS, and contributed as a Non-Executive Director at Cell Guidance Systems and Domain Therapeutics. Mark Treherne has a proven track record in drug discovery, biotherapeutics, and immuno-oncology, actively driving innovation to address unmet medical needs in various health domains.